Abstract
No public abstract is available from the verified source records.
Lars Køber, Anne‐Christine Ruwald, Daniela Tomasoni, Lisa Anderson, Jasper Jan Brugts, Ovidiu Chioncel, Erwan Donal, Péter Ferdinandy, Pardeep S. Jhund, Michael Madigan, Wilfried Mullens, Nicola Ryan, Maggie Simpson, Hölger Thiele, Jens Jakob Thune, Emeline M. Van Craenenbroeck, Linda Wilhelmina Van Laake, Mariëtte Verbakel, ESC Guidelines Advisory Group, Massimo Francesco Piepoli, Ana Abreu, Folkert W. Asselbergs, Michael Andrew Borger, Giuseppe Boriani, Robert A Byrne, Claudio Ceconi, Christina A. Chrysohoou, Kevin Damman, Jean‐Claude Deharo, Victoria Delgado, Fernando Dominguez, Daniel J. Fernandez-Berges, Marc Ferrini, Estelle Gandjbakhch, Luna Gargani, Borja Ibanez, Stefan Karl James, Ulf Landmesser, Gregory Y.H. Lip, Lars H. Lund, S MacDonald, John William McEvoy, Borislava Mihaylova, Inge Moelgaard, Christian Eugen Mueller, Lis Neubeck, Daniela Pini, Evgenij V Potapov, Anne–Catherine Pouleur, Eva Prescott, Amina Rakisheva, Bianca Rocca, Xavier Rosselló, Anna Sannino, Hatem Soliman-Aboumarie, Felix Christoph Tanner, Izabella Uchmanowicz, Mattias Van Heetvelde
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention
10.1093/eurheartj/ehaf009 · 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models
10.1093/eurheartj/ehaf016 · 2025
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · 2021
2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1161/cir.0000000000001063 · 2022
2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehad195 · 2023
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
10.1093/eurheartj/ehac244 · 2022
2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
10.1093/eurheartj/ehaf193 · 2025
2025 ESC Guidelines for the management of myocarditis and pericarditis
10.1093/eurheartj/ehaf192 · 2025
2025 ESC/EACTS Guidelines for the management of valvular heart disease
10.1093/eurheartj/ehaf194 · 2025
2024 ESC Guidelines for the management of chronic coronary syndromes
10.1093/eurheartj/ehae177 · 2024
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association
10.1002/ejhf.2115 · 2021
An update on global epidemiology in heart failure
10.1093/eurheartj/ehac248 · 2022
Global burden of heart failure: a comprehensive and updated review of epidemiology
10.1093/cvr/cvac013 · 2023
Prevalence, incidence and survival of heart failure: a systematic review
10.1136/heartjnl-2021-320131 · 2022
Insights into the European heart failure epidemiology
10.1002/ejhf.3710 · 2025
Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012
10.1161/circulationaha.116.025941 · 2017
Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals
10.1016/s0140-6736(17)32520-5 · 2018
Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990–2019
10.1093/ehjqcco/qcac088 · 2023
Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden
10.1093/eurheartj/eht278 · 2014
Epidemiology of heart failure in young adults: a French nationwide cohort study
10.1093/eurheartj/ehac651 · 2023
Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades
10.1016/j.jcmg.2017.08.007 · 2018
Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications
10.1016/j.jchf.2019.03.011 · 2019
Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions
10.1093/cvr/cvac179 · 2023
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction
10.1002/ejhf.3352 · 2024
Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study
10.1016/s2666-7568(24)00029-1 · 2024
Trends in heart failure mortality in Sweden between 1997 and 2022
10.1002/ejhf.3506 · 2024
Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals
10.1001/jamacardio.2019.3593 · 2019
Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes
10.1016/j.jacc.2017.08.074 · 2017
Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction
10.1016/j.amjcard.2015.07.018 · 2015
Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017
10.1093/ehjqcco/qcab073 · 2022
Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: a real-world study
10.1002/ehf2.13296 · 2021
A comprehensive population-based characterization of heart failure with mid-range ejection fraction
10.1002/ejhf.945 · 2017
Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study
10.1161/circheartfailure.117.003875 · 2017
Heart failure with mid-range or mildly reduced ejection fraction
10.1038/s41569-021-00605-5 · 2022
β Blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials
10.1016/s0140-6736(25)01592-2 · 2025
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
10.1093/eurheartj/ehx564 · 2018
Association between oral beta blocker therapy and long-term outcomes after myocardial infarction in individuals with mildly reduced or preserved left ventricular function: a meta-analysis of contemporary randomized controlled trials
10.1007/s10557-025-07826-7 · 2025
The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial
10.1177/1753944718809266 · 2018
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
10.1093/eurheartj/ehl250 · 2006
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
10.1002/ejhf.1149 · 2018
No additional external references are available.